Quest Diagnostics Incorporated has announced the launch of its first ctDNA minimal residual disease $(MRD.AU)$ test, Haystack MRD™, aimed at improving cancer monitoring for patients treated for solid tumors. The launch comes as part of a response to the increasing prevalence of advanced-stage cancers and the associated challenges in early detection of cancer recurrence. A recent survey conducted by The Harris Poll on behalf of Quest Diagnostics highlights that 76% of oncologists are observing more advanced cancers, with 94% believing that ctDNA MRD testing could significantly reduce delays in diagnosing cancer recurrence. Despite the promise of these new tests, oncologists acknowledge hurdles to their wide adoption. The Haystack MRD™ test is part of Quest Diagnostics' efforts to provide innovative solutions amid growing concerns of cancer recurrence among survivors, expected to reach 26 million by 2040.